Visceral leishmaniasis (kala-azar): Challenges ahead

Indian Journal of Medical Research

Volumn 123, Issue 3, 2006, Pages 331-344

  Singh, Rakeshbhu K ^a   Pandey, H P ^a   Sundar, S ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Control measures; Diagnosis; Drug resistant; Treatment; Visceral leishmaniasis

Indexed keywords

ABELCIT; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY DERIVATIVE; CYTOKINE; DNA; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PYRROLE DERIVATIVE; RECOMBINANT INTERFERON; SITAMAQUINE; STIBOGLUCONATE SODIUM; TRIAZOLE DERIVATIVE;

AGE; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; DIAGNOSTIC TEST; DIARRHEA; DNA DETERMINATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; IMMUNE RESPONSE; INCIDENCE; INDIA; INFECTION CONTROL; INSULIN DEPENDENT DIABETES MELLITUS; LEISHMANIA DONOVANI; MICROSCOPY; NEPHROTOXICITY; NONHUMAN; PARASITE TRANSMISSION; PATHOGENESIS; PHLEBOTOMUS; RANDOMIZATION; REVIEW; SEROLOGY; SHOCK; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VISCERAL LEISHMANIASIS; VOMITING;

AMINOQUINOLINES; AMPHOTERICIN B; ANIMALS; ANTIMONY; ANTIPROTOZOAL AGENTS; DRUG RESISTANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INDIA; LEISHMANIA; LEISHMANIASIS, VISCERAL; LIPIDS; PAROMOMYCIN; PUBLIC HEALTH; SENSITIVITY AND SPECIFICITY;

EID: 33745218506     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (140)

1. Desjeux P. Human leishmaniases: epidemiology and public health aspects. World Health Stat Q 1992; 45: 267-75.
2. Killick-Kendrick R. Phlebotomine vectors of the leishmaniases: a review. Med Vet Entomol 1990; 4: 1-24.
3. Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol 1996; 14: 417-23.
4. Ashford RW. The leishmaniases as model zoonoses. Ann Trop Med Parasitol 1997; 91: 693-701.
5. Magill AJ. Epidemiology of the leishmaniases. Dermatol Clin 1995; 13: 505-23.
6. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24: 684-703.
7. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001; 95: 239-43.
8. Bora D. Epidemiology of visceral leishmaniasis in India. Natl Med J India 1999; 12: 62-8.
9. Zijlstra EE, el-Hassan AM, Ismael A. Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg 1995; 52: 299-305.
10. Ramesh V, Mukherjee A. Post-kala-azar dermal leishmaniasis. Int J Dermatol 1995; 34: 85-91.
11. Kalter DC. Laboratory tests for the diagnosis and evaluation of leishmaniasis. Dermatol Clin 1994; 12: 37-50.
12. Chulay JD, Bryceson AD. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 1983; 32: 475-9.
13. Sundar S, Kumar K, Singh VP, Mahopatra TM. Diagnostic lag period in kala-azar: test for early diagnosis needed. J Assoc Physicians India 1991; 39: 651.
14. Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol 2002; 9: 951-8.
15. Lightner LK, Chulay JD, Bryceson AD. Comparison of microscopy and culture in the detection of Leishmania donovani from splenic aspirates. Am J Trop Med Hyg 1983; 32: 296-9.
16. Weigle KA, de Davalos M, Heredia P, Molineros R, Saravia NG, D'Alessandro A. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: a comparison of seven methods. Am J Trop Med Hyg 1987; 36: 489-96.
17. Navin TR, Arana FE, de Merida AM, Arana BA, Castillo AL, Silvers DN. Cutaneous leishmaniasis in Guatemala: comparison of diagnostic methods. Am J Trop Med Hyg 1990; 42: 36-42.
18. Sundar S, Pai K, Kumar R, Pathak-Tripathi K, Gam AA, Ray M, et al. Resistance to treatment in Kala-azar: speciation of isolates from northeast India. Am J Trop Med Hyg 2001; 65: 193-6.
19. Magill AJ, Grogl M, Gasser RA, Jr., Sun W, Oster CN. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med 1993; 328: 1383-7.
20. Grogl M, Daugirda JL, Hoover DL, Magill AJ, Berman JD. Survivability and infectivity of viscerotropic Leishmania tropica from Operation Desert Storm participants in human blood products maintained under blood bank conditions. Am J Trop Med Hyg 1993; 49: 308-15.
21. Kreutzer RD, Grogl M, Neva FA, Fryauff DJ, Magill AJ, Aleman-Munoz MM. Identification and genetic comparison of leishmanial parasites causing viscerotropic and cutaneous disease in soldiers returning from Operation Desert Storm. Am J Trop Med Hyg 1993; 49: 357-63.
22. Jaffe CL, McMahon-Pratt D. Serodiagnostic assay for visceral leishmaniasis employing monoclonal antibodies. Trans R Soc Trop Med Hyg 1987; 81: 587-94.
23. Sacks DL, Kenney RT, Kreutzer RD, Jaffe CL, Gupta AK, Sharma MC, et al. Indian kala-azar caused by Leishmania tropica. Lancet 1995; 345: 959-61.
24. Smyth AJ, Ghosh A, Hassan MQ, Basu D, De Bruijn MH, Adhya S, et al. Rapid and sensitive detection of Leishmania kinetoplast DNA from spleen and blood samples of kalaazar patients. Parasitology 1992; 105: 183-92.
25. Ilg T, Overath P, Ferguson MA, Rutherford T, Campbell DG, McConville MJ. O- and N-glycosylation of the Leishmania mexicana-secreted acid phosphatase. Characterization of a new class of phosphoserine-linked glycans. J Biol Chem 1994; 269: 24073-81.
26. Bray RS. Immunodiagnosis of leishmaniasis. In: Chang KP, Bray RS, editors. Leishmaniasis. Amsterdam, The Netherlands: Elsevier Science Publishers; 1985 p.177-81.
27. Aikat BK, Sehgal S, Mahajan RC, Pathania AG, Bhattacharya PK, Sahaya S, et al. The role of counter immunoelectrophoresis as a diagnostic tool in kala-azar. Indian J Med Res 1979; 70: 592-7.
28. Haldar JP, Saba KC, Ghose AC. Serological profiles in Indian post kala-azar dermal leishmaniasis. Trans R Soc Trop Med Hyg 1981; 75: 514-7.
29. Hockmeyer WT, Wellde BT, Sabwa CL, Smith DH, Rees PH, Kager PA. A complement fixation test for visceral leishmaniasis using homologous parasite antigen I. Ann Trop Med Parasitol 1984; 78: 489-93.
30. Sinha R, Sehgal S. Comparative evaluation of serological tests in Indian kala-azar. J Trop Med Hyg 1994; 97: 333-40.
31. Harith AE, Kolk AH, Kager PA, Leeuwenburg J, Faber FJ, Muigai R, et al. Evaluation of a newly developed direct agglutination test (DAT) for serodiagnosis and sero-epidemiological studies of visceral leishmaniasis: comparison with IFAT and ELISA. Trans R Soc Trop Med Hyg 1987; 81: 603-6.
32. Badaro R, Reed SG, Carvalho EM. Immunofluorescent antibody test in American visceral leishmaniasis: sensitivity and specificity of different morphological forms of two Leishmania species. Am J Trop Med Hyg 1983; 32: 480-4.
33. Harith AE, Kolk AH, Kager PA, Leeuwenburg J, Muigai R, Kiugu S, et al. A simple and economical direct agglutination test for serodiagnosis and sero-epidemiological studies of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1986; 80: 583-36.
34. Mengistu G, Kiessling R, Akuffo H. The value of a direct agglutination test in the diagnosis of cutaneous and visceral leishmaniasis in Ethiopia. Trans R Soc Trop Med Hyg 1990; 84: 359-62.
35. Zijlstra EE, Ali MS, el-Hassan AM, el-Toum IA, Satti M, Ghalib HW, et al. Kala-azar: a comparative study of parasitological methods and the direct agglutination test in diagnosis. Trans R Soc Trop Med Hyg 1992; 86: 505-7.
36. Zijlstra EE, Nut Y, Desjeux P, Khalil EA, El-Hassan AM, Groen J. Diagnosing visceral leishmaniasis with the recombinant k39 strip test: experience from the Sudan. Trop Med Int Health 2001; 6: 108-13.
37. Boelaert M, Rijal S, Regmi S, Singh R, Karki B, Jacquet D, et al. A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. Am J Trop Med Hyg 2004; 70: 72-7.
38. Sundar S, Singh GS, Singh VP, Singla N, Kumar K, Vinayak VK. Comparative evaluation of DAT, IFAT and micro-ELISA in the serodiagnosis of Indian Kala-azar. J Parasitic Dis 1996; 20: 41-3.
39. Vinayak VK, Mahajan D, Sobti RC, Singla N, Sundar S. Anti-66 kDa antileishmanial antibodies as specific immunodiagnostic probe for visceral leishmaniasis. Indian J Med Res 1994; 99: 109-14.
40. Singla N, Singh GS, Sundar S, Vinayak VK. Evaluation of the direct agglutination test as an immunodiagnostic tool for kala-azar in India. Trans R Soc Trop Med Hyg 1993; 87: 276-8.
41. Schoone GJ, Hailu A, Kroon CC, Nieuwenhuys JL, Schallig HD, Oskarn L. A fast agglutination screening test (FAST) for the detection of anti-Leishmania antibodies. Trans R Soc Trop Med Hyg 2001; 95: 400-1.
42. Badaro R, Benson D, Eulalio MC, Freire M, Cunha S, Netto EM, et al. rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis 1996; 173: 758-61.
43. Bern C, Jha SN, Joshi AB, Thakur GD, Bista MB. Use of the recombinant K39 dipstick test and the direct agglutination test in a setting endemic for visceral leishmaniasis in Nepal. Am J Trop Med Hyg 2000; 63: 153-7.
44. Burns JM, Jr., Shreffler WG, Benson DR, Ghalib HW, Badaro R, Reed SG. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc Natl Acad Sci USA 1993; 90: 775-9.
45. Choudhry A, Guru PY, Saxena RP, Tandon A, Saxena KC. Enzyme-linked immunosorbent assay in the diagnosis of kala-azar in Bhadohi (Varanasi), India. Trans R Soc Trop Med Hyg 1990; 84: 363-6.
46. Kumar R, Pai K, Pathak K, Sundar S. Enzyme-linked immunosorbent assay for recombinant K39 antigen in diagnosis and prognosis of Indian visceral leishmaniasis. Clin Diagn Lab Immunol 2001; 8: 1220-4.
47. Singh S, Gilman-Sachs A, Chang KP, Reed SG. Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis. J Parasitol 1995; 81: 1000-3.
48. Smrkovski LL, Larson CL. Antigenic cross-reactivity between Mycobacterium bovis (BCG) and Leishmania donovani. Infect Immun 1977; 18: 561-2.
49. Qu JQ, Guan LR, Shulidan I, Zuo XP, Chai JJ, Chen SB, et al. Rapid screening with a recombinant antigen (rK39) for diagnosis of visceral leishmaniasis using dipstick. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2000; 18: 155-8.
50. Jensen AT, Gasim S, Moller T, Ismail A, Gaafar A, Kemp M, et al. Serodiagnosis of Leishmania donovani infections: assessment of enzyme-linked immunosorbent assays using recombinant L. donovani gene B protein (GBP) and a peptide sequence of L. donovani GBP. Trans R Soc Trop Med Hyg 1999; 93: 157-60.
51. Rajasekariah GH, Ryan JR, Hillier SR, Yi LP, Stiteler JM, Cui L, et al. Optimisation of an ELISA for the serodiagnosis of visceral leishmaniasis using in vitro derived promastigote antigens. J Immunol Methods 2001; 252: 105-19.
52. Raj VS, Ghosh A, Dole VS, Madhubala R, Myler PJ, Stuart KD. Serodiagnosis of leishmaniasis with recombinant ORFF antigen. Am J Trop Med Hyg 1999; 61: 482-7.
53. Bhatia A, Daifalla NS, Jen S, Badaro R, Reed SG, Skeiky YA. Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi. Mol Biochem Parasitol 1999; 102: 249-61.
54. Sundar S, Reed SG, Singh VP, Kumar PC, Murray HW. Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet 1998; 351: 563-5.
55. Sundar S, Pai K, Sahu M, Kumar V, Murray HW. Immunochromatographic strip-test detection of anti-K39 antibody in Indian visceral leishmaniasis. Ann Trop Med Parasitol 2002; 96: 19-23.
56. Sundar S, Sahu M, Mehta H, Gupta A, Kohli U, Rai M, et al. Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. Clin Infect Dis 2002; 35: 581-6.
57. Goswami RP, Bairagi B, Kundu PK. K39 strip test - easy, reliable and cost-effective field diagnosis for visceral leishmaniasis in India. J Assoc Physicians India 2003; 51: 759-61.
58. De Colmenares M, Portus M, Riera. C, Gallego M, Aisa MJ, Torras S, et al. Short report: detection of 72-75-kD and 123-kD fractions of Leishmania antigen in urine of patients with visceral leishmaniasis. Am J Trop Med Hyg 1995; 52: 427-8.
59. Attar ZJ, Chance ML, el-Safi S, Carney J, Azazy A, El-Hadi M, et al. Latex agglutination test for the detection of urinary antigens in visceral leishmaniasis. Acta Trop 2001; 78: 11-6.
60. El Tai NO, El Fari M, Mauricio I, Miles MA, Oskam L, El Safi SH, et al. Leishmania donovani: intraspecific polymorphisms of Sudanese isolates revealed by PCR-based analyses and DNA sequencing. Exp Parasitol 2001; 97: 35-44.
61. Pizzuto M, Piazza M, Senese D, Scalamogna C, Calattini S, Corsico L, et al. Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type 1. J Clin Microbiol 2001; 39: 357-61.
62. Wortmann G, Sweeney C, Houng HS, Aronson N, Stiteler J, Jackson J, et al. Rapid diagnosis of leishmaniasis by fluorogenic polymerase chain reaction. Am J Trop Med Hyg 2001; 65: 583-7.
63. Chiurillo MA, Sachdeva M, Dole VS, Yepes Y, Miliani E, Vazquez L, et al. Detection of Leishmania causing visceral leishmaniasis in the Old and New Worlds by a polymerase chain reaction assay based on telomeric sequences. Am J Trop Med Hyg 2001; 65: 573-82.
64. Salotra P, Sreenivas G, Pogue GP, Lee N, Nakhasi HL, Ramesh V, et al. Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis. J Clin Microbiol 2001; 39: 849-54.
65. Singh N, Curran MD, Middleton D, Rastogi AK. Characterization of kinetoplast DNA minicircles of an Indian isolate of Leishmania donovani. Acta Trop 1999; 73: 313-9.
66. Lachaud L, Dereure J, Chabbert E, Reynes J, Mauboussin JM, Oziol E, et al. Optimized PCR using patient blood samples for diagnosis and follow-up of visceral leishmaniasis, with special reference to AIDS patients. J Clin Microbiol 2000; 38: 236-40.
67. Fisa R, Riera C, Ribera E, Gallego M, Portus M. A nested polymerase chain reaction for diagnosis and follow-up of human visceral leishmaniasis patients using blood samples. Trans R Soc Trop Med Hyg 2002; 96 (Suppl 1): S191-4.
68. Piarroux R, Gambarelli F, Dumon H, Fontes M, Dunan S, Mary C, et al. Comparison of PCR with direct examination of bone marrow aspiration, myeloculture, and serology for diagnosis of visceral leishmaniasis in immunocompromised patients. J Clin Microbiol 1994; 32: 746-9.
69. Cruz I, Canavate C, Rubio JM, Morales MA, Chicharro C, Laguna F, et al. A nested polymerase chain reaction (Ln-PCR) for diagnosing and monitoring Leishmania infantum infection in patients co-infected with human immunodeficiency virus. Trans R Soc Trop Med Hyg 2002; 96 (Suppl 1): S185-9.
70. Costa JM, Durand R, Deniau M, Rivollet D, Izri M, Houin R, et al. PCR enzyme-linked immunosorbent assay for diagnosis of leishmaniasis in human immunodeficiency virus-infected patients. J Clin Microbiol 1996; 34: 1831-3.
71. Cascio A, Calattini S, Colomba C, Scalamogna C, Galazzi M, Pizzuto M, et al. Polymerase chain reaction in the diagnosis and prognosis of Mediterranean visceral leishmaniasis in immunocompetent children. Pediatrics 2002; 109: E27-33.
72. Nuzum E, White F, 3rd, Thakur C, Dietze R, Wages J, Grogl M, et al. Diagnosis of symptomatic visceral leishmaniasis by use of the polymerase chain reaction on patient blood. J Infect Dis 1995; 171: 751-4.
73. Maurya R, Singh R, Kumar B, Salotra P, Rai M, Sundar S. Evaluation of PCR in the diagnosis and as predictor of cure in Indian Kala-azar. J Clin Microbiol 2005; 43: 3038-41.
74. Martin-Sanchez J, Pineda JA, Andreu-Lopez M, Delgado J, Macias J, De La Rosa R, et al. The high sensitivity of a PCR-ELISA in the diagnosis of cutaneous and visceral leishmaniasis caused by Leishmania infantum. Ann Trop Med Parasitol 2002; 96: 669-77.
75. Lachaud L, Chabbert E, Dubessay P, Reynes J, Lamothe J, Bastien P. Comparison of various sample preparation methods for PCR diagnosis of visceral leishmaniasis using peripheral blood. J Clin Microbiol 2001; 39: 613-7.
76. Osman OF, Kager PA, Zijlstra EE, el-Hassan AM, Oskam L. Use of PCR on lymph-node sample as test of cure of visceral leishmaniasis. Ann Trop Med Parasitol 1997; 91: 845-50.
77. Osman OF, Oskam L, Kroon NC, Schoone GJ, Khalil ET, El-Hassan AM, et al. Use of PCR for diagnosis of post-kala-azar dermal leishmaniasis. J Clin Microbiol 1998; 36: 1621-4.
78. le Fichoux Y, Quaranta JF, Aufeuvre JP, Lelievre A, Marty P, Suffia I, et al. Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. J Clin Microbiol 1999; 37: 1953-7.
79. Veeken H, Ritmeijer K, Seaman J, Davidson R. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health 2000; 5: 312-7.
80. Moore E, O'Flaherty D, Heuvelmans H, Seaman J, Veeken H, de Wit S, et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull World Health Organ 2001; 79: 388-93.
81. Peters W. The treatment of kala-azar - new approaches to an old problem. Indian J Med Res 1981; 73 (Suppl): 1-18.
82. Anonymous. Proceeding of the meeting of an Expert Group on Kala-azar held at Indian Council of Medical Research Headquarters on 9 September, 1977, New Delhi. Indian Council of Medical Research, New Delhi; 1977.
83. Aikat BK, Sahaya S, Pathania AG, Bhattacharya, PK, Desai N, Prasad LS, et al. Clinical profile of cases of kala-azar in Bihar. Indian J Med Res 1979; 70: 563-70.
84. Thakur CP, Kumar M, Singh SK, Sharma D, Prasad US, Singh RS, et al. Comparison of regimens of treatment with sodium stibogluconate in kala-azar. Br Med J (Clin Res Ed) 1984; 288: 895-7.
85. World Health Organization. The Leishmaniasis. Report of a WHO Expert Committee. World Health Organ Tec Rep Ser 1984; 701: 1-140.
86. Thakur CP, Kumar M, Pandey AK. Evaluation of efficacy of longer durations of therapy of fresh cases of kala-azar with sodium stibogluconate. Indian J Med Res 1991; 93: 103-10.
87. Jha TK, Singh NKP, Jha S. Therapeutic use of sodium stibogluconate in kala-azar from some hyperendemic districts of N. Bihar, India. J Assoc Physicians India 1992; 40: 868.
88. Sundar S, Rosenkaimer F, Lesser ML, Murray HW. Immunochemotherapy for a systemic intracellular infection: accelerated response usOing interferon-gamma in visceral leishmaniasis. J Infect Dis 1995; 171: 992-6.
89. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31: 1104-7.
90. Sundar S, Thakur BB, Tandon AK, Agrawal NR, Mishra CP, Mahapatra TM, et al. Clinicoepidemiological study of drug resistance in Indian kala-azar. BMJ 1994; 308: 307.
91. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6: 849-54.
92. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, et al. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 1999; 180: 564-7.
93. Frezard F, Demicheli C, Ferreira CS, Costa MA. Glutathione-induced conversion of 3pentavalent antimony to trivalent antimony in meglumine antimoniate. Antimicrob Agents Chemother 2001; 45: 913-6.
94. Shaked-Mishan P, Ulrich N, Ephros M, Zilberstein D. Novel intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. J Biol Chem 2001; 276: 3971-6.
95. Ouellette M, Legare D, Haimeur A., Grondin K, Roy G, Brochu C, et al. ABC transporters in Leishmania and their role in drug resistance. Drug Resistance Updates 1998; 1: 43-8.
96. Perez-Victoria JM, Di Pietro A, Barron D, Ravelo AG, Castanys S, Gamarro F. Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: a search for reversal agents. Curr Drug Targets 2002; 3: 311-33.
97. Legare D, Richard D, Mukhopadhyay R, Stierhof YD, Rosen BP, Haimeur A, et al. The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J Biol Chem 2001; 276: 26301-7.
98. Dey S, Ouellette M, Lightbody J, Papadopoulou B, Rosen BP. An ATP-dependent As(III)-glutathione transport system in membrane vesicles of Leishmania tarentolae. Proc Natl Acad Sci USA 1996; 93: 2192-7.
99. Perez-Victoria JM, Perez-Victoria FJ, Parodi-Talice A, Jimenez IA, Ravelo AG, Castanys S, et al. Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob Agents Chemother 2001; 45: 2468-74.
100. Perez-Victoria FJ, Castanys S, Gamarro F. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob Agents Chemother 2003; 47: 2397-403.
101. Perez-Victoria FJ, Gamarro F, Ouellette M, Castanys S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J Biol Chem 2003; 278: 49965-71.
102. Haimeur A, Brochu C, Genest P, Papadopoulou B, Ouellette M. Amplification of the ABC transporter gene PGPA and increased trypanothione levels in potassium antimonyl tartrate (SbIII) resistant Leishmania tarentolae. Mol Biochem Parasitol 2000; 108: 131-5.
103. Legare D, Papadopoulou B, Roy G, Mukhopadhyay R, Haimeur A, Dey S, et al. Efflux systems and increased trypanothione levels in arsenite-resistant Leishmania. Exp Parasitol 1997; 87: 275-82.
104. Haimeur A, Guimond C, Pilote S, Mukhopadhyay R, Rosen BP, Poulin R, et al. Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania. Mol Microbiol 1999; 34: 726-35.
105. Grondin K, Haimeur A, Mukhopadhyay R, Rosen BP, Ouellette M. Co-amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. EMBO J 1997; 16: 3057-65.
106. Carter KC, Sundar S, Spickett C, Pereira OC, Mullen AB. The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. Antimicrob Agents Chemother 2003; 47: 1529-35.
107. Singh N, Singh RT, Sundar S. Novel mechanism of drug resistance in kala-azar field isolates. J Infect Dis 2003; 188: 600-7.
108. Zilberstein D, Ephros M. Clinical and laboratory aspects of leishmania chemotherapy in the era of drug resistance. In: Seed J, editor. World class parasites. Vol. 4. London: Kluwer Academic Press; 2002 p. 115-36.
109. Jha TK. Evaluation of diamidine compound (pentamidine isethionate) in the treatment resistant cases of kala-azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg 1983; 77: 167-70.
110. Thakur CP, Kumar M, Pandey AK. Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study. Am J Trop Med Hyg 1991; 45: 435-41.
111. Jha SN, Singh NK, Jha TK. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. J Assoc Physicians India 1991; 39: 314-6.
112. Mishra M, Biswas UK, Jha DN, Khan A.B. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet 1992; 340: 1256-7.
113. Sundar S. Treatment of visceral leishmaniasis. Med Microbiol Immunol (Berl) 2001; 190: 89-92.
114. Nacher M, Carme B, Sainte Marie D, Couppie P, Clyti E, Guibert P, et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol 2001; 95: 331-6.
115. Correia D, Macedo VO, Carvalho EM, Barral A, Magalhaes AV, de Abreu MV, et al. Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis. Rev Soc Bras Med Trop 1996; 29: 447-53.
116. Amato V, Amato J, Nicodemo A, Uip D, Amato-Neto V, Duarte M. Treatment of mucocutaneous leishmaniasis with pentamidine isothionate. Ann Dermatol Venereol 1998; 125: 492-5.
117. Berman JD, Goad LJ, Beach DH, Holz GG, Jr. Effects of ketoconazole on sterol biosynthesis by Leishmania mexicana mexicana amastigotes in murine macrophage tumor cells. Mol Biochem Parasitol 1986; 20: 85-92.
118. Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharm Des 2002; 8: 319-42.
119. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 1999; 93: 319-23.
120. Heimenz J, Walsh TJ. Lipid formulations of Amphotericin B: recent progress and future directions. Clin Infect Dis 1996; 22: S133-44.
121. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002; 66: 143-6.
122. Thakur CP. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 2001; 17: 67-70.
123. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral lesihmaniasis with single or daily infusions of low dose liposomal Amphotericin B: randomized trial. BMJ 2001; 323: 419-22.
124. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003; 37: 800-4.
125. Zufferey R, Mamoun CB. Choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs. Mol Biochem Parasitol 2002; 125: 127-34.
126. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341: 1795-800.
127. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347: 1739-46.
128. Bhattacharya SK, Jha TK, Sundar S, Thakur CP, Engel J, Sindermann H, et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 2004; 38: 217-21.
129. Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J 2003; 22: 434-8.
130. Thakur CP, Olliaro P, Gothoskar S, Bhowmick S, Choudhury BK, Prasad S, et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 1992; 86: 615-6.
131. Thakur CP, Bhowmick S, Dolfi L, Olliaro P. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial. Trans R Soc Trop Med Hyg 1995; 89: 219-23.
132. Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Messick C, Olliaro P. Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg 2000; 94: 432-3.
133. Jha TK, Olliaro P, Thakur CP, Kanyok TP, Singhania BL, Singh IJ, et al. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 1998; 316: 1200-5.
134. Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Zaniewski AE, Houlihan HH, et al. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 2000; 94: 429-31.
135. Sherwood JA, Gachihi GS, Muigai RK, Skillman DR, Mugo M, Rashid JR, et al. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis 1994; 19: 1034-9.
136. Dietze R, Carvalho SF, Valli LC, Berman J, Brewer T, Milhous W, et al. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 2001; 65: 685-9.
137. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346: 891-5.
138. Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M, Hashim FA, el-Hassan AM, et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 1993; 92: 324-9.
139. Sundar S, Lesser ML, Sharma S, Mehrotra A, Murray HW. Circulating Th1 and Th2 cytokines in indian visceral lesihmaniasis. Am J Trop Med Hyg 1997; 56: 522-5.
140. Sundar S, Singh VP, Sharma S, Makharia MK, Murray HW. Response to interfero-r plus pentavalent antimony in Indian visceral lesihmaniasis. J Infect Dis 1997; 176: 1117-9.